Every Form 4 that AbbVie Inc. (ABBV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ABBV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABBV filings page.
AbbVie Inc. (ABBV) reported insider equity transactions by EVP and Chief Business/Strategy Officer Nicholas Donoghoe on August 14, 2026. Donoghoe exercised employee stock options for 32,710 shares of common stock at an exercise price of $79.02 per share under AbbVie’s 2013 incentive stock program, then sold 32,710 shares of common stock in a separate transaction. The options exercised were from a grant that vested in annual increments between 2020 and 2022 and now show 0 options remaining from this specific grant.
AbbVie Inc. director Edward J. Rapp reported receiving a grant of stock equivalent units as part of his board compensation. He acquired 134 stock equivalent units on June 30, 2026 at a reference value of $251.64 per unit, each tied to AbbVie common stock. Following this grant, his reported balance increased to 29,236 stock equivalent units, which earn the same return as if the fees were invested directly in AbbVie stock and include units added through a dividend reinvestment feature. These units are credited to a director grantor trust and are scheduled to be distributed over a period equal to his years of board service, generally beginning at the later of age 65 or retirement from the board.
AbbVie Inc. director Susan E. Quaggin reported a compensation-related award of stock equivalent units. On the reported date, she acquired 62 stock equivalent units tied to AbbVie common stock at 251.64 per unit, bringing her total balance to 853 stock equivalent units held directly.
The footnotes explain that director fees are credited to an unfunded book account in the director's name and are distributed over a period equal to the director's years of board service, generally starting at the later of age 65 or retirement from the board. These stock equivalent units earn the same return as if the fees were invested in AbbVie stock and the reported balance also includes units acquired through a dividend reinvestment feature.
FALK THOMAS J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Thomas J. Falk reported a compensation-related equity grant. He received 1,118 shares of AbbVie common stock at $0.00 per share as a grant of restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program. Following this award, he holds 2,321 AbbVie shares directly. The restricted stock units will be settled one-for-one in AbbVie shares upon the earlier of his separation from service, death, or a change in control as defined in the program. Separately, an additional 3,000 shares are owned indirectly through a limited partnership jointly controlled by Falk and his spouse, for which he disclaims beneficial ownership except for his pecuniary interest.
WADDELL FREDERICK H reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Frederick H. Waddell received an equity grant of 1,118 shares of AbbVie common stock in the form of restricted stock units. The award was granted at no cash cost to him as part of AbbVie’s incentive stock program.
The restricted stock units will be settled on a one-to-one basis in AbbVie shares upon the earlier of his separation from service, death, or a change in control as defined in the program. Following this grant, he directly holds 30,076 AbbVie shares.
Roberts Rebecca B reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Rebecca B. Roberts received a grant of 1,118 shares of common stock in the form of restricted stock units. These units were awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program and carry a zero-dollar grant price. After this grant, she directly holds 14,846 shares. The units will be settled on a one‑for‑one basis in AbbVie common stock upon the earlier of her separation from service, death, or a change in control as defined in the program.
AbbVie Inc. director Edward J. Rapp received an award of 1,118 restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program. Each unit will convert into one share of AbbVie common stock on the earlier of his separation from service, death, or a change in control as defined in the program. Following this grant, Rapp holds 45,964 AbbVie shares directly, including 10,388 shares previously held indirectly through a spouse’s trust that are now held directly.
Quaggin Susan E reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Susan E. Quaggin received an award of 1,118 restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program. The units will be settled in an equal number of AbbVie common shares upon the earlier of her separation from service, death, or a change in control as defined in the program.
Following this grant, she directly holds 3,643 shares of AbbVie common stock.
MEYER MELODY B reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Melody B. Meyer received an award of 1,118 shares of common stock in the form of restricted stock units. These units were granted at no cash cost to her and increase her directly owned holdings to 17,616 shares.
The restricted stock units were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and will be settled on a one-to-one basis in AbbVie common stock upon the earlier of her separation from service, death, or a change in control as defined in the program.
Hart Brett J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Brett J. Hart received an award of 1,118 shares of common stock in the form of restricted stock units. These units were granted at no cash cost to him and increase his direct holdings to 20,590 shares after the award.
The restricted stock units were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and will be settled one-for-one in AbbVie common stock. Settlement will occur on the earlier of his separation from service, death, or a change in control as defined in the program.
FREYMAN THOMAS C reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Thomas C. Freyman received a grant of 1,118 restricted stock units of AbbVie common stock at a stated price of $0.00 per share. After this award, he directly holds 127,869 shares of AbbVie common stock.
The restricted stock units were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and will be paid one-for-one in AbbVie shares upon the earlier of his separation from service, death, or a defined change in control. Additional AbbVie shares are held in trusts for his spouse and son, totaling 1,941 shares and 4,000 shares respectively, for which he disclaims beneficial ownership.
AbbVie Inc. director Jennifer L. Davis received an equity-based compensation award rather than buying shares on the market. She was granted 1,118 restricted stock units under AbbVie’s Amended and Restated 2013 Incentive Stock Program, increasing her reported direct holdings to 3,643 common shares. These units will convert into AbbVie stock on a one-to-one basis upon her separation from service, death, or a qualifying change in control, aligning her compensation more closely with long-term shareholder value.
BURNSIDE WILLIAM H.L. reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director William H.L. Burnside received a grant of 1,118 restricted stock units under the AbbVie Amended and Restated 2013 Incentive Stock Program. These units will be settled one-for-one in AbbVie common stock upon the earlier of separation from service, death, or a change in control, bringing his reported holdings to 28,076 shares.
AbbVie Inc. director Roxanne S. Austin received an award of 1,118 shares of common stock as a grant under the AbbVie Amended and Restated 2013 Incentive Stock Program. Following this compensation-related acquisition, she beneficially owns 39,576 AbbVie common shares directly.
According to the award terms, these are restricted stock units that will be paid on a one-to-one basis in AbbVie common shares upon the earlier of her separation from service, death, or a change in control as defined in the program.
Quaggin Susan E reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Susan E. Quaggin reported a compensation-related award of 71 stock equivalent units tied to AbbVie common stock at a reference value of $217.49 per unit. Following this grant, her balance in these units increased to 784 stock equivalent units.
The units represent director fees credited to a stock equivalent unit account under a grantor trust established by the director and are generally paid in cash at around age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock, and the balance also reflects units accumulated through a dividend reinvestment feature.
RAPP EDWARD J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Edward J. Rapp received a grant of 155 Stock Equivalent Units on March 31, 2026. The units were credited as director fees at a reference price of $217.49 per unit and are linked to AbbVie common stock performance.
Following this grant, Rapp holds a reported total of 28,865 Stock Equivalent Units. These units are maintained in a grantor trust established by the director and are generally paid in cash at age 65 or upon retirement from the board, with value tracking AbbVie stock, including a dividend reinvestment feature.
Alpern Robert J reported acquisition or exercise transactions in this Form 4 filing.
AbbVie Inc. director Robert J. Alpern received a grant of 35 stock equivalent units tied to AbbVie common stock as director compensation. The units were credited on the basis of director fees at a reference value of $217.49 per unit and track the return of AbbVie shares.
Following this award, Alpern’s balance increased to 10,369 stock equivalent units held in grantor trust accounts. These units are payable in cash, generally at age 65 or when he retires from the AbbVie board, and the balance also reflects units added through a dividend reinvestment feature.
AbbVie Inc. senior vice president and controller David Ryan Purdue reported a routine tax-related share disposition. On February 27, 2026, 2,108 shares of AbbVie common stock were withheld at $232.08 per share to cover tax obligations, a non-market transaction coded as a tax-withholding disposition.
After this event, Purdue directly held 8,468 shares of AbbVie common stock. He also had an additional 543 shares held indirectly through a profit sharing trust tied to an AbbVie savings program, with that balance stated as of February 20, 2026 and including shares from dividend reinvestment.
AbbVie Inc. senior vice president and controller David Ryan Purdue sold 5,230 shares of AbbVie common stock in an open-market transaction at $233.56 per share on March 4, 2026. After the sale, he directly held 2,654 shares.
A separate entry shows 543 AbbVie shares held directly in an AbbVie Savings program as of February 20, 2026, with that balance including shares acquired through a dividend reinvestment feature.
AbbVie Inc. executive Demetris D. Crum, EVP and Chief HR Officer, reported a tax-related share disposition. On February 27, 2026, Crum disposed of 1,594 shares of AbbVie common stock at $232.08 per share to satisfy tax withholding obligations, a non‑open‑market transaction coded as a tax‑withholding disposition. After this event, Crum directly owned 7,914 AbbVie shares.
AbbVie Inc. executive Roopal Thakkar reported a tax-related share disposition. On February 27, 2026, 8,037 shares of AbbVie common stock were disposed of at $232.08 per share to cover tax obligations, leaving 52,376 directly held shares. The filing also reports 2,998 shares held indirectly through a profit sharing trust, reflecting the balance in the AbbVie Savings program as of February 20, 2026, including dividend reinvestment shares that were previously omitted from an earlier Form 3.
AbbVie Inc. director and CEO Michael Robert A. reported a Form 4 transaction involving a tax-related share disposition. On February 27, 2026, he had 36,523 shares of common stock disposed of at $232.08 per share to satisfy tax obligations. After this tax-withholding disposition, he directly owned 178,737 shares of AbbVie common stock.
AbbVie Inc. executive vice president and chief commercial officer Jeffrey Ryan Stewart reported a tax-withholding disposition of 23,812 shares of common stock at $232.08 per share on February 27, 2026. After this transaction, he directly owned 83,171 shares. An additional 1,338 shares are held indirectly by his spouse in a trust, and he disclaims beneficial ownership of those securities.
AbbVie Inc. executive Perry C. Siatis, EVP, GC and Secretary, reported several stock transactions. On February 27, 2026, he disposed of 14,850 common shares at $232.08 per share to cover tax obligations. On March 2, 2026, he conducted open-market sales totaling 18,668 common shares at weighted average prices between about $233 and $235.36. Following these sales, his directly owned common stock holdings were reported in the filing at reduced levels after each transaction.
AbbVie Inc. executive vice president and chief financial officer Scott T. Reents reported a tax-related share disposition under a compensation plan. On February 27, 2026, 21,638 shares of AbbVie common stock were disposed of to cover tax withholding obligations. After this transaction, he directly owned 38,777 AbbVie shares.
AbbVie Inc. executive Azita Saleki‑Gerhardt reported a tax-related share disposition. On February 27, 2026, 16,309 shares of AbbVie common stock were disposed of at $232.08 per share to satisfy tax obligations through share withholding, a non‑open‑market transaction. Following this, she directly held 197,794 AbbVie shares.
In addition, 2,706 AbbVie shares were held indirectly through a profit sharing trust, reflecting the balance in the AbbVie Savings Program as of February 20, 2026, including dividend reinvestments. A further 3,873 shares were held by her spouse, for which the reporting person disclaims beneficial ownership.
AbbVie Inc. senior vice president and controller David Ryan Purdue reported a tax-related share disposition. On February 27, 2026, he transferred 2,692 shares of AbbVie common stock at $232.08 per share to cover tax obligations, described as a payment of tax liability by delivering securities.
After this transaction, he directly owned 7,884 shares of AbbVie common stock. He also had an indirect holding of 543 shares through a profit sharing trust, with a footnote noting this balance in an AbbVie savings program as of February 20, 2026, including shares acquired via a dividend reinvestment feature.
AbbVie Inc. executive Nicholas Donoghoe reported a tax-related share disposition under a compensation plan. On February 27, 2026, he used 12,874 shares of common stock, valued at $232.08 per share, to cover tax withholding. After this transaction, he directly held 74,430 shares of AbbVie common stock.
AbbVie Inc. executive Perry C. Siatis, EVP, General Counsel and Secretary, reported multiple stock option exercises and a related share sale. On February 25, 2026, he exercised options covering 7,314, 7,775 and 7,292 AbbVie shares at exercise prices of $149.62, $175.28 and $192.86 per share under the AbbVie Amended and Restated 2013 Incentive Stock Program. These exercises delivered an equal number of AbbVie common shares. On the same date, he sold 22,381 AbbVie shares in an open-market transaction at $230.00 per share. After these transactions, Siatis directly held 38,137 AbbVie common shares.
AbbVie Inc. reported that EVP, R&D and CSO Roopal Thakkar acquired new equity awards through grants rather than open-market trades. On February 18, 2026, Thakkar received an employee stock option for 21,937 AbbVie shares, exercisable in three annual installments of 7,313, 7,312 and 7,312 shares in 2027, 2028 and 2029.
On the same date, Thakkar also acquired several performance-based AbbVie common stock awards, including grants of 6,015, 2,138, 3,346 and 6,638 shares. These awards were tied to performance goals such as earnings per share, relative total shareholder return and relative return on equity. The Compensation Committee certified that the goals were met, releasing the performance-vesting restrictions, with the shares scheduled to be issued on February 28, 2026.
AbbVie Inc. senior vice president and controller David Ryan Purdue reported multiple equity awards and holdings changes. On February 18, 2026, he acquired an option to buy 4,875 shares of AbbVie common stock at an exercise price set by the company’s incentive plan, recorded at $0.00 per share for reporting purposes.
On the same date, he also acquired several blocks of AbbVie common stock as grants or awards: 2,505 shares, 890 shares, 1,292 shares, and 1,384 shares, all reported at $0.00 per share as they were issued under performance-based share and restricted stock unit awards. Footnotes explain these awards were tied to earnings per share, relative total shareholder return, and relative return on equity goals, with vesting confirmed by AbbVie’s Compensation Committee and the shares scheduled to be issued on February 28, 2026.
The filing also notes 543 shares of AbbVie common stock held indirectly through a profit sharing trust as part of the AbbVie savings program as of February 20, 2026, including shares acquired via dividend reinvestment. The employee stock option vests in annual increments of 1,625 shares on February 18 of 2027, 2028, and 2029.
AbbVie Inc. executive Jeffrey Ryan Stewart, EVP and Chief Commercial Officer, reported awards of stock options and performance-based shares on February 18, 2026. He acquired an option to buy 26,812 shares that vests in three annual installments starting in February 2027, plus multiple performance-vesting stock and restricted stock unit awards tied to earnings per share, relative total shareholder return, and relative return on equity, with shares scheduled to be issued on February 28, 2026. An additional 1,338 shares are held indirectly by his spouse in a trust, for which he disclaims beneficial ownership.
AbbVie Inc. executive Perry C. Siatis, EVP, GC and Secretary, reported multiple equity awards in AbbVie common stock. On February 18, 2026, he acquired several performance-based share awards, including 5,792, 5,628, 5,808 and 16,290 shares, all at a stated price of $0.00 per share.
Footnotes explain these represent performance-vesting awards and restricted stock units granted in 2023, 2024 and 2025, tied to earnings per share, relative total shareholder return and relative return on equity. The performance conditions were certified as achieved, and the related shares are scheduled to be issued on February 28, 2026. He also received an employee stock option covering 19,500 shares, vesting in three equal annual installments starting in 2027.
AbbVie Inc. executive vice president and chief operations officer Azita Saleki-Gerhardt reported equity compensation grants. She received an employee stock option for 20,312 shares at a grant price of $0.00, vesting in three annual installments of 6,771, 6,771 and 6,770 shares on February 18, 2027, February 18, 2028, and February 18, 2029.
She also acquired multiple blocks of AbbVie common stock through performance-based share and restricted stock unit awards, with grants from February 16, 2023, February 15, 2024, and February 13, 2025 tied to earnings per share, relative total shareholder return, and relative return on equity. These performance-vesting restrictions were certified as attained on February 18, 2026, and the shares will be issued on February 28, 2026. Additional indirect holdings include shares in an AbbVie savings program and shares held by her spouse, for which she disclaims beneficial ownership.
AbbVie Inc. executive Demetris D. Crum, EVP and Chief HR Officer, reported equity compensation awards rather than open-market trades. On February 18, 2026, Crum was granted options for 13,406 shares of AbbVie common stock under the AbbVie Amended and Restated 2013 Incentive Stock Program. These options become exercisable in three annual installments of 4,469 shares on February 18, 2027, 4,469 shares on February 18, 2028, and 4,468 shares on February 18, 2029.
Crum also acquired 1,216 shares and 1,244 shares of AbbVie common stock tied to performance-vesting restricted stock unit awards originally granted on February 15, 2024 and February 13, 2025, respectively. These awards vest based on a relative return on equity measure, with performance certified by AbbVie’s Compensation Committee, and the shares are scheduled to be issued on February 28, 2026.
AbbVie executive Nicholas Donoghoe reported multiple equity awards tied to performance goals. On February 18, 2026, he acquired an option to buy 20,312 AbbVie shares, vesting in three equal annual installments starting on February 18, 2027.
He also received performance-based stock awards of 13,031, 4,632, 5,172 and 6,222 AbbVie shares. These stock units vested after AbbVie’s Compensation Committee certified achievements in earnings per share, relative total shareholder return and relative return on equity, with shares scheduled to be issued on February 28, 2026.
AbbVie Inc. executive vice president and chief financial officer Scott T. Reents reported equity awards that increase his direct stake in the company. On February 18, 2026, he acquired an option for 21,937 shares of AbbVie common stock at an exercise price set by the plan, with the option vesting in annual increments of 7,313 shares on February 18, 2027 and 7,312 shares on February 18, 2028 and February 18, 2029. He was also credited with multiple performance-based share and restricted stock unit awards totaling 48,838 shares of common stock, granted in 2023, 2024, and 2025. These awards vested after AbbVie’s Compensation Committee certified the achievement of performance goals tied to earnings per share, relative total shareholder return, and relative return on equity, and the underlying shares are scheduled to be issued to him on February 28, 2026.
AbbVie Inc. reported that Chief Executive Officer Michael Robert A. acquired new equity incentives in the form of stock options and performance-based stock awards. On February 18, 2026, he received an option grant for 81,251 shares at an exercise price listed as $0.00 per share, which reflects an incentive award structure rather than a market purchase.
He was also credited with several performance-vesting share awards of AbbVie common stock tied to prior grants. These include 33,833 shares from a performance share award granted on February 16, 2023, and additional performance-vesting restricted stock unit awards of 12,030, 14,452 and 22,124 shares from grants dated February 16, 2023, February 15, 2024 and February 13, 2025. The performance conditions were based on earnings per share, relative total shareholder return and relative return on equity, and were certified by the Compensation Committee, releasing the vesting restrictions.
The shares from these performance-based awards are scheduled to be issued to the CEO on February 28, 2026. The stock option becomes exercisable in three annual installments of 27,084 shares on February 18, 2027, 27,084 shares on February 18, 2028, and 27,083 shares on February 18, 2029.
AbbVie Inc. director Robert J. Alpern reported a routine compensation-related transaction. On 12/31/2025, he acquired 34 stock equivalent units tied to AbbVie common stock at $228.49 per unit, bringing his total holdings of these derivative securities to 10,257 stock equivalent units.
According to the disclosure, these units represent director fees credited to stock equivalent unit accounts under grantor trusts established at Abbott Laboratories and AbbVie. The units are paid out in cash, generally at age 65 or upon retirement from each company’s board, and earn the same return as if the fees were invested in AbbVie stock. The reported balance also reflects units acquired through a dividend reinvestment feature.
AbbVie Inc. director equity filing: A Form 4 reports that a director of AbbVie received 68 stock equivalent units on 12/31/2025 at a reference value of $228.49 per unit. These units are credited as director fees into a stock equivalent unit account in a grantor trust and are generally paid in cash at about age 65 or upon retirement from the board. After this transaction, the director beneficially owns 707 stock equivalent units, which are designed to earn the same return as if the fees were invested directly in AbbVie common stock, including through a dividend reinvestment feature.
AbbVie Inc. director Edward J. Rapp reported an acquisition of stock equivalent units tied to AbbVie stock. On 12/31/2025, 147 stock equivalent units were credited at a price of $228.49 per unit, bringing his total directly held derivative securities reported on this form to 28,498 stock equivalent units.
The units represent director fees credited to a stock equivalent unit account under a grantor trust established by the director and are paid in cash generally at age 65 or upon retirement from the board. These stock equivalent units earn the same return as if the fees were invested in AbbVie stock, and the reported balance includes units acquired through a dividend reinvestment feature.
Susan E. Quaggin, an AbbVie Inc. (ABBV) director, had 67 stock equivalent units credited to her account on 09/30/2025 at a unit value of $231.54. The filing shows these units are held in a grantor trust and are paid in cash generally at age 65 or upon retirement from the board; they earn returns as if invested in AbbVie stock. The report indicates a post-transaction beneficial ownership balance of 634 shares (including units acquired through a dividend reinvestment feature).
Robert J. Alpern, an AbbVie director, reported a Form 4 disclosing a non‑derivative acquisition on 09/30/2025 of 33 stock equivalent units credited at a per‑unit value of $231.54. The filing states these units are director fees credited to grantor trust accounts established by Abbott Laboratories and AbbVie and that AbbVie account units are payable in cash generally at age 65 or upon retirement from AbbVie’s board. The report shows a total beneficial ownership balance of 10,151 stock equivalent units (including amounts from dividend reinvestment). The Form 4 was signed by an attorney‑in‑fact on 10/02/2025.